Table 3.
Distribution of etiological agents versus microbiologically defined infections and clinically defined infections.
| Infection | Microorganism | n (%) |
|---|---|---|
| Bacteraemia (n:34) | E.coli | 9 (26.4%) |
| Acinetobacter spp. | 4 (11.7%) | |
| S. aureus | 4 (11.7%) | |
| Enterococcus spp. | 5 (14.7%) | |
| S. pneumoniae | 4 (11.7%) | |
| CoNS | 4 (13.5%) | |
| Pseudomonas spp | 3 (8.8%) | |
| Proteus mirabilis | 1 (2.9%) | |
| Urinary tract infection (n:23) | Candida spp. | 12 (46.1%) |
| E. coli | 5 (19.2%) | |
| Enterococcus spp. | 5 (26.9%) | |
| Pseudomonas spp. | 1 (3.8%) | |
| Pneumonia (n:15) | Stenotrophomonas maltophilia | 4 (26.6%) |
| E.coli | 2 (13.3%) | |
| Acinetobacter spp. | 2 (13.3%) | |
| S. aureus | 2 (13.3%) | |
| S. pneumoniae | 2 (13.3%) | |
| Aspergillus spp. | 2 (13.3%) | |
| Candida spp. | 1 (6.6%) | |
| Proven sinusitis | Aspergillus flavus | 1(100%) |
| Probable Aspergillus pneumonia | 2 | |
| Possible aspergillosis | 22 | |
| 3rd generation cephalosporin-resistant Gram-negative (n:10) | E. coli | 4 (40%) |
| K. pneumoniae | 1 (10%) | |
| Enterobacter cloacae | 1 (10%) | |
| Proteus mirabilis | 1 (10%) | |
| Pseudomonas spp. | 1 (10%) | |
| Stenotrophomonas maltophilia | 2 (20%) | |
| Methicillin-resistant staphylococci (n:11) | Coagulase negative staphylococci | 7 (63.6%) |
| S.aureus | 4 (36.4%) | |
| CDI (n:61) | Skin and soft tissue infection | 40 (65.6%) |
| Pneumonia | 21 (34.4%) |
CDI clinically documented infection.
Significant values are in (italic).